Effect of combined spironolactoneβ-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF Study)

American Journal of Cardiology

Volumn 106, Issue 11, 2010, Pages 1609-1614

  Dabrowski, Rafal ^a   Borowiec, Anna ^a   Smolis Bak, Edyta ^a   Kowalik, Ilona ^a   Sosnowski, Cezary ^a   Kraska, Alicja ^a   Kazimierska, Barbara ^a   Wozniak, Jacek ^a   Zareba, Wojciech ^b   Szwed, Hanna ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; PROPRANOLOL; SPIRONOLACTONE;

AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENALAPRIL; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; PROSPECTIVE STUDIES; SPIRONOLACTONE; TACHYCARDIA, PAROXYSMAL; TREATMENT OUTCOME;

EID: 78649322746     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.07.037     Document Type: Article

References (16)

1. A. Goette, T. Staack, C. Rocken, M. Arndt, J.C. Geller, C. Huth, S. Ansorge, H.U. Klein, and U. Lendeckel Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation J Am Coll Cardiol 35 2000 1669 1677
2. F. Musgrave, and H. Majewski Evidence that angiotensin II enhances noradrenaline releases from sympathetic nerves in mouse atria by activating protein kinase C J Auton Pharmacol 11 1991 211 221
3. K. Asano, D.L. Dutcher, J.D. Port, W.A. Minobe, K.D. Tremmel, R.L. Roden, T.J. Bohlmeyer, E.W. Bush, M.J. Jenkin, W.T. Abraham, M.V. Raynolds, L.S. Zisman, M.B. Perryman, and M.R. Bristow Selective downregulation of the angiotensin II at-1 receptor subtype in failing human ventricular myocardium Circulation 95 1997 1193 1200
4. H.R. Black Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data Am Heart J 147 2004 564 572
5. A.D. Struthers Aldosterone: cardiovascular assault Am Heart J 144 2002 S2 S7
6. E. Harada, M. Yoshimura, H. Yasue, O. Nakagawa, M. Nakagawa, M. Harada, Y. Mizuno, M. Nakayama, Y. Shimasaki, T. Ito, S. Nakamura, K. Kuwahara, Y. Saito, K. Nakao, and H. Ogawa Aldosterone induces angiotensin-converting enzyme gene expression in cultured neonatal rat cardiocytes Circulation 104 2001 137 139
7. B.M.W. Schmidt, and R.E. Schmmieder Aldosterone-induced cardiac damage: focus on blood pressure independent effects Am J Hypertens 16 2003 80 86
8. C.S. Barr, C.C. Lang, J. Hanson, M. Arnott, N. Kennedy, and A.D. Struthers Effects of adding spironolactone to an ACE inhibitor in chronic congestive heart failure secondary to coronary artery disease Am J Cardiol 76 1995 1259 1265
9. A. Goette, P. Hoffmanns, W. Enayati, U. Meltendorf, J.C. Geller, and H.U. Klein Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation Am J Cardiol 88 2001 906 909
10. P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, and J.J. Mourad Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 2005 1243 1248
11. P. Milliez, N. DeAngelis, C. Rucker-Martin, A. Leenhardt, E. Vicaut, E. Robidel, P. Beaufils, C. Delcayre, and S.N. Hatem Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction Eur Heart J 26 2005 2193 2199
12. B.A. Schaer, C. Schneider, S.S. Jick, D. Conen, S. Ossswald, and C.R. Meier Risk for incident AF in patients who receive antihypertensive drugs Ann Intern Med 152 2010 78 84
13. M.P. Schneider, T.A. Hua, M. Bhm, K. Wachtell, S.E. Kjeldsen, and R.E. Schmieder Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis J Am Coll Cardiol 55 2010 2299 2307
14. D. Traub, J.P. Daubert, S. McNitt, W. Zareba, and B. Hall Catheter ablation of atrial fibrillation in the elderly: where do we stand? Cardiol J 16 2009 113 120
15. G.S. Kamath, and J.S. Steinberg Cardiac resynchronization therapy and atrial fibrillation Cardiol J 16 2009 4 10
16. F.T. Han, V. Kasirajan, M.A. Wood, and K.A. Ellenbogen Minimally invasive surgical atrial fibrillation ablation: patient selection and results Heart Rhythm 12 2009 S71 S76